Who
Neil K. Warma
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, ProMIS Neurosciences; President, CEO and Acting CFO, Opexa Therapeutics.
In numbers
- Trades disclosed
- 44
- Buys
- 3
- Sells
- 0
- Bought
- $24K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 11 Aug 2008
- Last trade
- 20 May 2026
- Last filed
- 22 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 20 May 2026filed 22 May 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —160,000 at $0.00 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Code A | $75K6,183 at $12.13 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,183 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,183 | filing |
| 3 Feb 2026filed 5 Feb 2026 | PMN ProMIS NeurosciencesBiotechnology | SEC FORM 4 Code A | $75K6,183 at $12.13 | filing |
| 22 Sep 2025filed 24 Sep 2025 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —600,000 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,144,122 at $0.00 | filing |
| 8 Oct 2024filed 10 Oct 2024 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —490,338 at $0.00 | filing |
| 2 Jan 2024filed 5 Jan 2024 | PMN ProMIS Neurosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 16 May 2016filed 18 May 2016 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 8 Apr 2015filed 9 Apr 2015 | Opexa Therapeutics | SEC FORM 4 Code M | —37,247 | filing |
| 8 Apr 2015filed 9 Apr 2015 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code M | —37,247 at $0.00 | filing |
| 8 Apr 2015filed 9 Apr 2015 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code M | —37,247 | filing |
| 2 Mar 2015filed 4 Mar 2015 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 16 Sep 2014filed 17 Sep 2014 | Opexa Therapeutics | SEC FORM 4 Bought | $11K10,000 at $1.11 | filing |
| 28 Feb 2014filed 4 Mar 2014 | Opexa Therapeutics | SEC FORM 4 Code A | —51,748 at $0.00 | filing |
| 28 Feb 2014filed 4 Mar 2014 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code A | —316,250 at $0.00 | filing |
| 8 Nov 2013filed 12 Nov 2013 | Opexa Therapeuticsoption or derivative | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 8 Nov 2013filed 12 Nov 2013 | Opexa Therapeutics | SEC FORM 4 Code A | —28,571 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.